Literature DB >> 24250986

Association Between Apo Lipoprotein B Levels at Admission of Patients and Short-term Morbidity and Mortality After Myocardial Infarction.

Sepideh Sokhanvar1, Amirhossein Khoshi, Sanaz Hajiaghaei, S Nouraddin Mousavinasab, Zahra Golmohammadi.   

Abstract

INTRODUCTION: Dyslipidemia is an important risk factor in cardiovascular diseases. Different studies have shown that Apolipoprotein B (Apo B) is one of the best predictors in determining cardiovascular diseases and patients follow up after cardiovascular events. We hypothesized that there is a relation between Apo B levels and cardiovascular events in patients who have myocardial infarction (MI). In addition, Apo B may be an appropriate marker for following these patients after MI.
METHODS: In this study, 220 patients with acute myocardial infarction were allocated at their admission to the hospital. They were followed for three months after MI and their morbidity and mortality rates were evaluated. Apo B levels were measured immunoturbidimetrically.
RESULTS: Apo B levels were significantly higher in patients with the events including coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI) and malignant arrhythmias (P = 0.001).
CONCLUSION: Apo B levels can be an appropriate indicator of cardiovascular events in patients after MI.

Entities:  

Keywords:  CABG; Cardiovascular Morbidity; PCI

Year:  2012        PMID: 24250986      PMCID: PMC3825361          DOI: 10.5681/jcvtr.2012.015

Source DB:  PubMed          Journal:  J Cardiovasc Thorac Res        ISSN: 2008-5117


  16 in total

1.  High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.

Authors:  G Walldius; I Jungner; I Holme; A H Aastveit; W Kolar; E Steiner
Journal:  Lancet       Date:  2001-12-15       Impact factor: 79.321

2.  Apolipoprotein B as the best predictor of coronary artery disease in Iranian normolipidemic patients.

Authors:  M Haidari; M Moghadam; M Chinicar; A Ahmadieh; M Doosti
Journal:  Clin Biochem       Date:  2001-03       Impact factor: 3.281

Review 3.  Apolipoproteins as markers and managers of coronary risk.

Authors:  D C Chan; G F Watts
Journal:  QJM       Date:  2006-02-27

Review 4.  Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus.

Authors:  A D Sniderman; T Scantlebury; K Cianflone
Journal:  Ann Intern Med       Date:  2001-09-18       Impact factor: 25.391

Review 5.  Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype.

Authors:  M A Austin
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

6.  The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk.

Authors:  Göran Walldius; Ingmar Jungner; Are H Aastveit; Ingar Holme; Curt D Furberg; Allan D Sniderman
Journal:  Clin Chem Lab Med       Date:  2004       Impact factor: 3.694

7.  Plasminogen activator inhibitor-1 polymorphism (4G/5G) predicts recurrence in nonhyperlipidemic postinfarction patients.

Authors:  James P Corsetti; Dan Ryan; Arthur J Moss; David L Rainwater; Wojciech Zareba; Charles E Sparks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-12-20       Impact factor: 8.311

8.  Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study.

Authors:  J H Contois; J R McNamara; C J Lammi-Keefe; P W Wilson; T Massov; E J Schaefer
Journal:  Clin Chem       Date:  1996-04       Impact factor: 8.327

Review 9.  Molecular bases of coronary heart disease in Koreans.

Authors:  J Q Kim; J Song; Y B Park; S H Hong
Journal:  J Korean Med Sci       Date:  1998-02       Impact factor: 2.153

10.  Serum lipid profile constituents as markers of cardiovascular morbidity in patients on chronic hemodialysis.

Authors:  Dimitrios Kirmizis; Evangelia Koutoupa; Apostolos Tsiandoulas; Aphroditi Valtopoulou; Georgios Niavis; Phani Markou; Konstantinos Barboutis
Journal:  Biomark Insights       Date:  2007-02-07
View more
  3 in total

1.  Serum concentrations of cholecystokinin, peptide YY, ghrelin and high sensitive C-reactive protein in association with metabolic syndrome ingredients in obese individuals.

Authors:  M Mesgari-Abbasi; M Abbasalizad Farhangi
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Jan-Mar       Impact factor: 0.877

2.  Dietary diversity score is associated with cardiovascular risk factors and serum adiponectin concentrations in patients with metabolic syndrome.

Authors:  Mahdieh Abbasalizad Farhangi; Leila Jahangiry
Journal:  BMC Cardiovasc Disord       Date:  2018-04-17       Impact factor: 2.298

3.  Powdered black cumin seeds strongly improves serum lipids, atherogenic index of plasma and modulates anthropometric features in patients with Hashimoto's thyroiditis.

Authors:  Mahdieh Abbasalizad Farhangi; Parvin Dehghan; Siroos Tajmiri
Journal:  Lipids Health Dis       Date:  2018-03-27       Impact factor: 3.876

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.